Belimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase 3 BLISS-52 and -76 studies - Manzi, S; Sanchez-Guerrero, J; Merrill, JT (Arthritis Rheum, 2010)
et al.